KO vs PFE: Which Is the Better Buy?

Side-by-side comparison of The Coca-Cola Company and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-07-17.

The Coca-Cola Company · Consumer Defensive

$84.92

-10.2% upside to fair value

Grade C High Quality

PFE

Pfizer Inc. · Healthcare

$25.22

+2.8% upside to fair value

Grade B

QuantHub Verdict

PFE has more upside to fair value (+2.8%). PFE trades at a lower forward P/E (19.2x). These are model outputs — not personalized investment advice. See all research →

Valuation & Fundamentals

Metric	KO	PFE
Current Price	$84.92	$25.22
Fair Value Estimate	$76.30	$25.92
Upside to Fair Value	-10.2%	+2.8%
Market Cap	$365.4B	$143.7B
Forward P/E	26.6x	19.2x
EV / EBITDA	20.7x	12.3x
Price / Sales	7.4x	2.3x
Price / FCF	29.1x	15.2x
Revenue Growth YoY	+12.1%	+5.4%
Gross Margin	61.7%	69.3%
Operating Margin	29.3%	23.4%
Return on Equity	43.6%	8.4%
Dividend Yield	0%	0%
FCF Yield	3.44%	6.6%
Analyst Consensus	Strong Buy	Hold

Investment Thesis

KO — The Coca-Cola Company

The Coca-Cola Company is a leading global beverage company specializing in non-alcoholic drinks with a durable competitive moat driven by its strong brand and extensive distribution network. The business quality is high, evidenced by a 43.6% return on equity, robust gross margin of 61.7%, and solid revenue and earnings growth of 12.1% and 17.8% respectively in the most recent quarter. Despite the…

PFE — Pfizer Inc.

Pfizer Inc. is a leading global biopharmaceutical company with a diversified portfolio dominated by its Biopharma prescription segment, which accounts for over 90% of revenue. The company benefits from a substantial scale, a broad product portfolio including top-selling drugs like Eliquis, Prevnar, and Paxlovid, and a strong manufacturing footprint. However, Pfizer faces challenges from declining…

Accumulation Zones

Metric	KO	PFE
Zone Low	$57.22	$19.44
Zone High	$64.85	$22.03
In Buy Zone?	No	No

← KO Research PFE Research → All Research